Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27816728 | 1.00 | CDK1 (0.46) | CDK1CCNB1PTGS1GAAKDM4E | |
| SCHEMBL27816729 | 1.00 | CDK1 (0.46) | CDK1CCNB1PTGS1GAAKDM4E | |
| SCHEMBL10936650 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL15641934 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL28223754 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL24529121 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL10936641 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL15641935 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL2835425 | 0.95 | PTGS1 (0.48) | PTGS1GAAKDM4EPOLBMAPT | |
| SCHEMBL17961878 | 0.90 | AMY2A (0.40) | CDK1CCNB1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582659-B2 | Stimulant composition and process for making same | ALL LABS, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260007677-A1 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | VAE LABS INC. (CA) | 2026-01-08 | — | — | US | claimed |
| US-12433894-B2 | Stimulant composition and process for making same | ALL LABS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-12074000-B2 | Iron chromophores for energy conversion | DUKE UNIVERSITY (US) | 2024-08-27 | — | — | US | claimed |
| CN-116407547-A | Active ingredient Rosavins in rhodiola rosea, preparation containing Rosavins and application of preparation | 鼎元(天津)生物医药科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | IMMUNOLIGHT, LLC (US) | 2023-06-29 | — | — | US | claimed |
| US-20220362320-A1 | METHODS FOR PREPARING EXTRACTS FROM PLANTS AND FUNGI | CANNA STREAM SOLUTIONS LTD. (CA) | 2022-11-17 | — | — | US | claimed |
| US-20220241289-A1 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | ALL LABS, INC. | 2022-08-04 | — | — | US | claimed |
| US-20220028624-A1 | Iron Chromophores for Energy Conversion | DUKE UNIVERSITY | 2022-01-27 | — | — | US | claimed |
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | WHITEHEAD INST FOR BIOMEDICAL RESEARCH (US) | 2026-05-21 | — | — | US | disclosed |
| US-12582659-B2 | Stimulant composition and process for making same | ALL LABS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260007677-A1 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | VAE LABS INC. (CA) | 2026-01-08 | — | — | US | disclosed |
| US-12515067-B2 | Non-invasive systems and methods for selective activation of photoreactive responses | IMMUNOLIGHT, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-12433894-B2 | Stimulant composition and process for making same | ALL LABS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-10258658-B2 | Compositions and methods for improved muscle metabolism | NATUREX SA (FR) | 2019-04-16 | — | — | US | disclosed |
| US-20170296605-A1 | COMPOSITIONS AND METHODS FOR IMPROVED MUSCLE METABOLISM | NATUREX SA (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9700589-B2 | Compositions and methods for improved muscle metabolism | NATUREX SA (FR) | 2017-07-11 | — | — | US | disclosed |
| US-20160220624-A1 | Compositions and Methods for Improved Muscle Metabolism | NATUREX SA (FR) | 2016-08-04 | — | — | US | disclosed |
| WO-2013020368-A1 | RHODIOLA ROSEA EXTRACTS AND ISOLATED COMPOUNDS AND USES THEREOF FOR TREATING NEURODEGENERATIVE DISEASES | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201624-A1 | NON-INVASIVE ENERGY UPCONVERSION METHODS AND SYSTEMS FOR IN-SITU PHOTOBIOMODULATION | MAVS, NLN, FURIN | CDK1 2274/4885CCNB1 3261/4885PTGS1 1287/4885 |
| US-20220241289-A1 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | COMT, TH, TYR | CDK1 751/4885CCNB1 1409/4885PTGS1 3057/4885 |
| US-12582659-B2 | Stimulant composition and process for making same | SLC18A2, S100B, ADORA2B | CDK1 393/4885CCNB1 59/4885PTGS1 3988/4885 |
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | COMT, UGDH, GUSB | CDK1 3541/4885CCNB1 1938/4885PTGS1 1620/4885 |
| US-20260007677-A1 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | SLC6A6, SLC6A2, SLC6A12 | CDK1 439/4885CCNB1 87/4885PTGS1 3920/4885 |
| US-12433894-B2 | Stimulant composition and process for making same | COMT, TH, TYR | CDK1 764/4885CCNB1 1418/4885PTGS1 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.